CMH Wealth Management LLC Sells 1,575 Shares of Eli Lilly and Company (NYSE:LLY)

CMH Wealth Management LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,297 shares of the company's stock after selling 1,575 shares during the quarter. Eli Lilly and Company makes up about 2.5% of CMH Wealth Management LLC's investment portfolio, making the stock its 11th largest position. CMH Wealth Management LLC's holdings in Eli Lilly and Company were worth $10,156,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Moss Adams Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 10.9% in the 1st quarter. Moss Adams Wealth Advisors LLC now owns 2,810 shares of the company's stock worth $2,321,000 after buying an additional 276 shares during the period. Wiser Wealth Management Inc lifted its holdings in Eli Lilly and Company by 7.5% in the 1st quarter. Wiser Wealth Management Inc now owns 316 shares of the company's stock worth $261,000 after buying an additional 22 shares during the period. NewSquare Capital LLC lifted its holdings in Eli Lilly and Company by 89.2% in the 1st quarter. NewSquare Capital LLC now owns 350 shares of the company's stock worth $289,000 after buying an additional 165 shares during the period. Greystone Financial Group LLC lifted its holdings in Eli Lilly and Company by 7.1% in the 1st quarter. Greystone Financial Group LLC now owns 916 shares of the company's stock worth $757,000 after buying an additional 61 shares during the period. Finally, McDonough Capital Management Inc raised its position in shares of Eli Lilly and Company by 18.8% in the 1st quarter. McDonough Capital Management Inc now owns 744 shares of the company's stock worth $615,000 after acquiring an additional 118 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.4%

Shares of LLY stock traded up $3.01 during mid-day trading on Thursday, hitting $811.62. The company's stock had a trading volume of 2,264,167 shares, compared to its average volume of 3,645,503. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The business has a 50-day moving average price of $771.74 and a 200 day moving average price of $800.91. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $769.20 billion, a price-to-earnings ratio of 69.31, a PEG ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the firm earned $2.58 EPS. The business's revenue was up 45.2% on a year-over-year basis. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

A number of research firms have recently commented on LLY. UBS Group lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.